<PAGE>

EXHIBIT 99.1

                PRIVATE SECURITIES LITIGATION REFORM ACT OF 1995
                        SAFE HARBOR COMPLIANCE STATEMENT
                         FOR FORWARD-LOOKING STATEMENTS

     In passing the Private Securities Litigation Reform Act of 1995 (the
"Reform Act"), 15 U.S.C.A. Sections 77z-2 and 78u-5 (Supp. 1996), Congress
encouraged public companies to make "forward-looking statements" by creating a
safe harbor to protect companies from securities law liability in connection
with forward-looking statements. Pvaxx Corporation ("PVAXX" or the
"Company") intends to qualify both its written and oral forward-looking
statements for protection under the Reform Act and any other similar safe
harbor provisions.

     "Forward-looking statements" are defined by the Reform Act. Generally,
forward-looking statements include expressed expectations of future events and
the assumptions on which the expressed expectations are based. All forward-
looking statements are inherently uncertain as they are based on various
expectations and assumptions concerning future events and they are subject to
numerous known and unknown risks and uncertainties which could cause actual
events or results to differ materially from those projected. Due to those
uncertainties and risks, the investment community is urged not to place undue
reliance on written or oral forward-looking statements of Pvaxx. The
Company undertakes no obligation to update or revise this Safe Harbor Compliance
Statement for Forward-Looking Statements (the "Safe Harbor Statement") to
reflect future developments. In addition, PVAXX undertakes no obligation
to update or revise forward-looking statements to reflect changed assumptions,
the occurrence of unanticipated events or changes to future operating results
over time.

     PVAXX provides the following risk factor disclosure in connection with
its continuing effort to qualify its written and oral forward-looking statements
for the safe harbor protection of the Reform Act and any other similar safe
harbor provisions. Important factors currently known to management that could
cause actual results to differ materially from those in forward-looking
statements include the disclosures contained in the Quarterly Report on
Form 10-QSB to which this statement is appended as an exhibit and also
include the following:

<PAGE>

Technology Uncertainty and Lack of Market Acceptance

Although PVA-based polymers (like PVAXX(R)) and other polymers have been
developed by various pharmaceutical or plastics manufacturing companies to
replace conventional plastics, relatively limited research has been conducted
in the expansion of PVA-based and other polymers to a wider range of products.
The Company has commenced market-study surveys and sold and shipped
comparatively small orders to potential customers for evaluation by those
potential customers.  However, there can be no guarantee that any of the
potential customers currently evaluating PVAXX(R) will actually purchase any
more PVAXX(R).  Additionally, although Management believes that the Company
has demonstrated in initial manufacturing trials that PVAXX(R) may be capable
of being used to produce a broad range of products, PVA-based polymers are
currently marketed for only a limited number of products.  PVAXX(R) is subject
to the risks of failure inherent in the development and marketing of products
based on innovative technologies.  These risks include the possibilities that
any or all of the proposed uses for PVAXX(R) may be found to be ineffective,
or otherwise may fail to receive necessary regulatory clearances; that
PVAXX(R), although effective, may be uneconomical to market; or that third
parties may market superior or equivalent products.  Due to the current lack
of acceptance of PVAXX(R) by manufacturers of plastics products, the Company
does not expect to be able to realize significant revenues from the sale of
PVAXX(R) in the near term.


Our Company does not have significant experience in international distribution
that may negatively impact our plan of operation and selling strategies.

Our Company intends to sell PVAXX(R) through an international distribution
strategy. The Company is currently negotiating with several distributors
experienced in international distribution of products, but no decision as to
which distributor will be utilized, or the terms of the distribution contract,
has yet been made.  There can be no guarantees that the Company will be able
to secure a suitable distributor on terms favorable to the company.  Failure
to secure a relationship with an international distributor could have an
adverse affect on the Company's ability to successfully market PVAXX(R) and,
ultimately, the Company's operations.  Additionally, the Company's operations
will be subject to the wide range of general business risks associated with
international operations, including;

-unexpected changes in legal and regulatory requirements;
-changes in tariffs, exchange rates and other barriers;
-political and economic instability;
-inability to repatriate net income from foreign markets;
-difficulty in protecting the Company's intellectual property; and
-potentially adverse tax consequences.

<PAGE>

Additionally, the Company has not had pilot overseas distribution projects.
Such inexperience combined with various other international manufacturing
risks could cause our Company's attempted international growth strategy to
fail, causing a material adverse affect to the operations of the Company.

Our Company does not have significant experience in foreign currency and foreign
exchange regulation that may adversely affect our results of operations.

Our Company intends, although there can be no assurance, to arrange for the
distribution of a significant amount of products throughout the world. We may
be required to accomplish such transactions through the use of foreign
currencies, directly or indirectly. We do not currently engage in currency
exchange rate hedging transactions. To the extent, however, that our Company
may engage in any such hedging transactions in the future, there can be no
assurance that any currency hedging policies implemented by the Company in
the future will be successful.  As a result, fluctuations in exchange rates
of the U.S. dollar, the Euro or British pound against foreign currencies
could adversely affect our results of operations.


Our Company may experience significant risks relating to the use of
foreign suppliers.

The Company intends, although there can be no assurance, to arrange for the
manufacture of PVAXX(R) overseas. Such overseas manufacturing will be
dependent upon foreign suppliers.  The Company will not have contractual
agreements with suppliers.  Prices for and supply of those products may be
adversely affected by changing economic conditions internationally.
Without a contract setting a specific price or price range, fluctuations in
price could reduce the Company's profit margin resulting in adverse effects
to the Company's operations.

Our Company may also be subject to other risks associated with its international
relationships, including tariff regulations and requirements for export
licenses, unexpected changes in regulatory requirements, potentially adverse
tax consequences, economic and political instability, restrictions on
repatriation of earnings and the burdens of complying with a wide variety of
foreign laws. In addition, the laws of certain countries may not protect our
products and intellectual property rights to the same extent as the laws of the
United States or the United Kingdom. There can be no assurance that such
factors will not have a material adverse effect on our Company's future sales
or licenses and, consequently, on the Company's business, prospects, results
of operations or financial condition as a whole.

If our Company cannot establish and maintain commercial relationships with
suppliers of raw materials, we will not be able to produce our product.

Our Company does not have any oral or written contracts or agreements with
suppliers of our raw materials. In the event that a relationship with a
supplier upon which we depend is terminated, there can be no guarantee that
we will be able to locate other satisfactory suppliers, or even if other
suppliers could be located, that we will be able to establish and/or continue
commercial relationships with any such suppliers on favorable terms, if at
all. If we are unable to establish commercial relationships with other
suppliers, we may not be able to produce our products. In addition, our
products principal raw materials are currently readily available, but
there can be no guarantee that a general shortage of such raw materials will
not occur. Such a shortage could also suspend or curtail some of our
operations. In the event we cannot secure such raw materials or any other raw
materials on reasonable commercial terms, we may have to go to other sources
and may not be able to secure similar quality or prices. Any suspension or
curtailment of raw materials could have a material adverse effect on our
Company.

We have experienced losses since inception, expect future losses and may
not become profitable.

We have incurred losses since inception. To date, we have experienced no
significant revenues from the sale of our product and expect this trend to
continue until some indefinite date in the future. We may not become
profitable. If we do achieve profitability, we may not be able to
sustain or increase profitability on a quarterly or annual basis.


We may require additional capital in the future that may not be available.

Our future capital requirements will depend on many factors, including:

-   the cost of manufacturing scale-up;
-   the scope of market acceptance of our products
-   the timing of market acceptance of our products;
-   competing technological and market developments; and
-   the costs involved in filing, prosecuting and enforcing patent claims.

There is uncertainty as to our future profitability that may make it difficult
for us to secure additional financing on acceptable terms, if we are able to
secure additional financing at all. Insufficient funds may require us to delay,
scale back or eliminate some or all of our activities or to obtain funds
through arrangements with third parties that may require us to relinquish rights
to some or all of our technologies, product candidates or products that we
would otherwise seek to develop or commercialize ourselves.

The market for polymers such as PVAXX(R) is made up of companies which have
significantly greater financial, technical and human resources and market
products that are well-established and accepted, which may make our Company
unable to compete in the marketplace.

There are many manufacturers of plastic polymers whose products are competitive
with PVAXX in that they are currently being used by manufacturers of end-stage
products.  While PVAXX will provide an alternative raw material with
significant environmental benefits, the products of our competitors are well
entrenched.  In addition,  many of our competitors have significantly greater
financial, technical and human resources than we do, which may diminish any
competitive advantage that we may currently have over them.  Currently, the
company does not give samples of its products away.  Rather it sells smaller
quantities to manufacturers for their evaluation and testing.  Our competitors
may succeed in obtaining market acceptance for products more rapidly than we
do in addition to having volume manufacturing efficiency and marketing
capabilities, areas in which we have limited or no experience.

The primary source of competition for our PVAXX(R) product currently comes
from suppliers of conventional non-degradable plastic products. The use of
non-degradable products is well-established and accepted by both consumers
and the industry, many of which may be indifferent to the benefits offered
by our products. Many of our competitors who provide these non-degradable
products have significantly greater financial, technical and human resources
than we do. Changes in political and consumer emphasis on environmental
factors in waste disposal could significantly harm our competitive position
relative to these established solutions with respect to some of our products
whose principal advantage is degradability. Such changes may be imminent in
light of the current United States political climate, the unlikelihood of
increased United States environmental regulation and the possibility of a
reduction in United States environmental regulation.

We are largely dependent on Henry Stevens, our Chairman, and may not be able
to continue to attract, retain and motivate highly skilled personnel.

Our success depends to a significant extent upon the continued service of
Henry Stevens, our founder and Chairman.  Mr. Stevens has been intimately
involved in the research and development of PVAXX from the beginning.  His
loss of service to our Company could have a material adverse effect on our
business or results of operations. Currently, Mr. Stevens is under contract
with us, through 2006.

Demand notes between the Company and affiliates may have an adverse impact
on our financial condition.

The Company's Principal shareholder, Jumik Investments, holds a non-interest
bearing, unsecured demand note obligating the Company to repay, upon demand,
loans made by Jumik to the Company.  As of December 31, 2000, the balance on
this note was approximately $1million. While Jumik does not currently intend
to call the note due, there can be no assurances that they will not demand
the note.  A demand could have an adverse effect on the Company's financial
condition.

The Company's Chairman, Henry Stevens, holds a non-interest bearing, unsecured
demand note obligating the Company to pay, upon demand, his deferred salary,
as well as repay a loan made by Mr. Stevens to the Company.  The current
balance of this note, as of December 31, 2000, was approximately $530,000.
While Mr. Stevens does not currently intend to call the note due, there can
be no assurances that he will not demand the note.  A demand could have an
adverse effect on the company's financial condition.

Our early development stage may lead to potential fluctuations in quarterly
operating results that could have a material adverse effect on business,
prospects, financial condition and results of operations.

Our business and prospects must be considered along with the risks, expenses
and difficulties frequently encountered by polymer manufacturing companies in
their early stages of development. The risks we face include, but are not
limited to,

(a) our product's performance;
(b) general economic conditions and economic conditions specific to the
    biodegradable plastics industry;
(c) our ability to manage rapid growth;
(d) our ability to anticipate and adapt to a developing market and unforeseen
    changes;
(e) developments in our strategic partners' activities and direction;
(f) our ability to retain and attract customers;
(g) the level of competition in the biodegradable plastics industry;
(h) our ability to upgrade and develop its product and infrastructure and
    attract new personnel in a timely and effective manner;
(i) the amount and timing of operating costs and capital expenditures relating
    to expansion of our business, operations and infrastructure; and
(j) governmental regulation.

To address these risks, we must, among other things:

(a) implement and successfully execute our business strategy;
(b) continue to develop and upgrade our products and technology;
(c) provide superior customer service;
(d) respond to competitive developments;
(e) attract, retain and motivate qualified personnel; and
(f) meet the expectations of our strategic partners.

There can be no assurance that we will be successful in addressing such risks,
and the failure to do so could have a material adverse effect on our business,
prospects, financial condition and results of operations.

There can be no assurance that we will secure, or be able to protect any
patents, trademarks or intellectual property.

On November 24, 2000, the Company  received an International Preliminary
Examination Report regarding International application No. PCT/GB99/02822,
originally filed August 26, 1999 regarding its patent applications to protect
different grades of PVAXX(R). Reasoned statements under Article 35(2) with
regard to novelty, inventive step and industrial applicability were confirmed
favorably by the International Preliminary Examining Authority on all claims
asserted (1-30) in connection with the application as follows:

         Novelty                     Yes:             Claims     1-30
                                      No:             Claims        -
         Inventive step (IS)         Yes:             Claims     1-30
                                      No:             Claims        -
         Industrial applicability    Yes:             Claims     1-30
                                      No:             Claims        -

The Company through its wholly-owned subsidiary, PVAXX Technologies, Ltd. is
also the holder of the rights to patents published under International
Publication Numbers WO 98/26911 on June 25, 1998 and WO 00/12615 on
March 9, 2000.

The Company has applied for trademark protection on July 20, 2000, Application
No.  2240024 in the United Kingdom and all other major-developed countries
for the name "PVAXX". There can be no assurance that existing or future patents
or trademarks, if any, will adequately protect the Company. Also, there can be
no assurances that any patent or trademark applications will result in issued
patents or trademarks.  In addition, there can be no assurances that the
Company's patents or trademarks will be upheld, if challenged. The Company
also faces the risk that competitors will develop similar or superior methods
or products outside the protection of any patent issued to the Company.
Although the Company believes that its current European patents and trademarks,
potential United States patent and trademarks, as well as the Company's
products, do not and will not infringe patents or trademarks or violate the
proprietary rights of others, it is possible that the Company's existing
patent or trademark rights may not be valid or that infringement of existing
or future patents, trademarks or proprietary rights may occur.  Failure to do
any of the foregoing could have a material adverse effect upon the Company.

In addition, there can be no assurance that the Company will have the financial
or other resources necessary to enforce or defend a patent or trademark
infringement or proprietary rights violation action that may be brought against
it. Moreover, if the Company's products infringe patents, trademarks or
proprietary rights of others, the Company could, under certain circumstances,
become liable for damages, which also could have a material adverse effect on
the Company.

The control of the Company by principal shareholders, officers and directors
could impede its shareholders from having any ability to direct affairs and
business.

Our principal shareholders, officers and directors will beneficially own
approximately seventy-four percent (74%) of our Company's common stock.  As
a result, such persons will have the ability to control our Company and
direct its affairs and business.  Such concentration of ownership may also
have the effect of delaying, deferring or preventing change in control of our
company.

Jumik Investments' ownership and Henry Stevens' control of preferred stock
may adversely affect holders of common stock or delay or prevent corporate
takeovers.

Our Articles of Incorporation provide that we may, from time to time, issue
preferred stock in one or more series. The Articles of Incorporation authorize
our Board of Directors to determine the rights, preferences, privileges and
restrictions granted to and imposed upon any wholly unissued series of
preferred stock and the designation of any such shares, without any vote or
action by our shareholders.  The Board of Directors may authorize and issue
Preferred stock with voting power or other rights that could adversely affect
the voting power or other rights of the holders of common stock.  Presently,
Jumik Technologies, Ltd ("JUMIK") owns all of the issued and outstanding
preferred stock.  Mr Stevens, the Company's Chairman, holds a controlling
interest in JUMIK and, as such, controls the preferred stock.  Mr. Stevens
control of the preferred stock could delay, defer or prevent a change in
control of the Company, because the terms of preferred stock could potentially
prohibit the Company's consummation of any merger, reorganization, sale of
substantially all of its assets, liquidation or other extraordinary corporate
transaction without the approval of the holders of the outstanding shares of
the preferred stock.

Our stock price will be potentially volatile and may impede our ability to
secure equity financing or complete business combination transactions on
favorable terms to the Company.

There has been no public market for our common stock. There can be no assurance
that an active trading market will develop or be sustained. At a future date,
provided a public market for the stock does develop, the market price of the
shares of common stock is likely to be highly volatile and may be significantly
affected by factors such as fluctuations in the Company's operating results,
announcements of technological innovations or new products and/or services by
the Company or its competitors, governmental regulatory action, developments
with respect to patents or proprietary rights and general market conditions.
In addition, the stock market has, from time to time, experienced significant
price and volume fluctuations that are unrelated to the operating performance
of particular companies.  Significant fluctuations may impede our ability to
secure equity financing or complete business combination transactions on
favorable terms to the Company.

Our Company's indemnification of officers and directors may result in
substantial expenditures by the Company

Our Articles of Incorporation provide for the indemnification of directors,
officers, employees, and agents, under certain circumstances, against
attorney's fees and other expenses incurred by them in any litigation to
which they become a party arising from their association with or activities
on behalf of the Company.  We will also bear the expenses of such litigation
for any directors, officers, employees, or agents, upon such person's promise
to repay the Company therefore if it is ultimately determined that any such
person shall not have been entitled to indemnification.  This indemnification
policy could result in substantial expenditures by the Company that it will
be unable to recoup.

Required regulatory disclosure relating to low-priced stocks may negatively
impact liquidity in our common stock.

While the initial offering price is $10.00, there may be downward pressure due
to lack of demand for the Company's stock or from the Selling Shareholders.
Should the trading price of the common stock drop to less than US$5.00 per
share, trading in the common stock in the US secondary market would be subject
to certain rules promulgated under the Securities Exchange Act of 1934, which
rules require additional disclosure by broker-dealers in connection with any
trades involving a stock defined as a "penny stock" (generally, any non-NASDAQ
equity security that has a market price of less than US$5.00 per share,
subject to certain exceptions).  Such rules require the delivery, prior to any
penny stock transaction, of a disclosure schedule explaining the penny stock
market and the risks associated therewith, and impose various sales practice
requirements on broker-dealers who sell penny stocks to persons other than
established customers and accredited investors. For these types of transactions,
the broker-dealer must make a special suitability determination for the
purchaser and have received the purchaser's written consent to the
transactions prior to sale.

The additional burdens imposed upon broker-dealers by such requirements may
discourage broker-dealers from effecting transactions in our common stock,
which could severely limit the market liquidity and the ability of
stockholders to sell the common stock in the US secondary market.

Current prospectus and state blue sky requirements may impede our ability to
offer common stock in certain jurisdictions.

We will be able to issue shares of its common stock only if there is then a
current prospectus relating to such common stock and only if such common
stock is qualified for sale or exempt from qualification under applicable
state securities laws of the jurisdictions in which the various holders of
the common stock reside. We have undertaken and intend to file and keep
current a prospectus that will permit the purchase and sale of the common
stock, but there can be no assurance that we will be able to do so. Although
we intend to seek to qualify for sale the shares of common stock in those
states in which the securities are to be offered, no assurance can be given
that such qualification will occur. The common stock may be deprived of any
value and the market for such shares may be limited if a current prospectus
covering the common stock is not kept effective or if such common stock is
not qualified or exempt from qualification in the jurisdictions in which the
holders then reside.